| Purpose:Colorectal cancer is a common malignant tumor of the gastrointestinal tract,seriously threatens human health and longevity[1].Surgery is an important method for the treatment of mid-advanced colorectal cancer.However,since even after the primary tumor is removed,may cause reduced load on cancer cells,residual cancer cells also undergo hemodynamic changes within 24 hours,the proportion of cancer cells will increase significantly,therefore,currently in clinical practice,patients are often given effective chemotherapy after surgery to control the patient’s condition,extend patient survival[2].Research shows[3],adjuvant chemotherapy after radical colorectal cancer surgery,can effectively control the progression of patients with colon cancer,reduces adverse effects from colon cancer and surgery,and can improve the quality of life of patients.The application effect of XELOX chemotherapy in adjuvant chemotherapy for colorectal cancer has been recognized at home and abroad.However,the selection of the timing of postoperative adjuvant chemotherapy has been clinically lacking in standards.Therefore,the research in this paper is based on the guidance of ERAS,to analyze the effect of early XELOX adjuvant chemotherapy in colorectal cancer patients,To determine the best time for adjuvant chemotherapy after colorectal cancer,to provide a reference for clinicians to help patients with colorectal cancer achieve a better prognosis.Methods:From January 2016 to December 2017,60 patients who received radical surgeryfor colorectal cancer in the former People’s Liberation Army No.101 Hospital were selected as study samples.30 cases were included in the routine group by random double-blind method.The remaining 30 patients were included in the early group,Controlled studies were performed in both groups.All patients in this experiment underwent radical laparoscopic surgery for colorectal cancer.There are30 cases in the experimental group.Begin adjuvant chemotherapy within 2 weeks after surgery;30 cases in the control group,Adjuvant chemotherapy was started around 4 weeks after surgery.The perioperative period of the two groups of patients were treated according to the ERAS procedure.XELOX three-week chemotherapy was used for postoperative adjuvant chemotherapy.Observe the adverse reactions at 12 and 18 months after surgery in both groups.The recurrence rate,distant metastasis rate,and survival rate were calculated at 24 months after surgery.The main adverse reactions were peripheral neurotoxicity,nausea,vomiting,diarrhea and hand-foot syndrome.Results:The difference in baseline data between the two groups was statistically tested to show P> 0.05.There were no cases of anastomotic leakage,celiac infection,interruption of treatment,or adjustment of treatment plan during the postoperative chemotherapy in the two groups of patients.The incidence of adverse reactionsat 12 months after surgery in the early group was higher than that in the conventional group(P<0.05).There were no significant differences in various adverse reactions at18 months after operation(P> 0.05).Relapse rate(0.00%),distant metastasis rate(3.33%),and survival rate(96.67%)in the early group within 24 months were not significantly different from those in the conventional group(3.33%,6.67%,93.33%)(P> 0.05).Conclusion:Guided by the concept of ERAS,Adjuvant chemotherapy with XELOX in patients with colorectal cancer can not improve their 24 month survival rate and reduce their ecurrence rate 、 distant metastasis rate at 24 months after surgery.But it mayincrease the incidence of adverse reactions in patients 12 months after surgery.The incidence of adverse reactions at 18 months after surgery was equal to that of patients receiving conventional XELOX chemotherapy.Early XELOX adjuvant chemotherapy may have some impact on the long-term prognosis of patients with colorectal cancer after surgery,which will be further studied to make clear. |
